Mackenzie Financial’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.7M | Buy |
86,394
+14,962
| +21% | +$2.86M | 0.02% | 463 |
|
|
2026
Q1 | $13.1M | Buy |
71,432
+357
| +0.5% | +$65.8K | 0.02% | 476 |
|
|
2025
Q4 | $12.5M | Buy |
71,075
+7,321
| +11% | +$1.2M | 0.01% | 461 |
|
|
2025
Q3 | $8.93M | Sell |
63,754
-18,582
| -23% | -$2.51M | 0.01% | 517 |
|
|
2025
Q2 | $10.3M | Buy |
82,336
+35,652
| +76% | +$4.44M | 0.01% | 473 |
|
|
2025
Q1 | $6.39M | Buy |
46,684
+12,838
| +38% | +$1.84M | 0.01% | 529 |
|
|
2024
Q4 | $5.18M | Buy |
33,846
+19,759
| +140% | +$3.33M | 0.01% | 567 |
|
|
2024
Q3 | $2.73M | Sell |
14,087
-11,577
| -45% | -$2.42M | ﹤0.01% | 661 |
|
|
2024
Q2 | $5.95M | Sell |
25,664
-21,558
| -46% | -$4.69M | 0.01% | 513 |
|
|
2024
Q1 | $10.2M | Sell |
47,222
-13,404
| -22% | -$3.14M | 0.01% | 435 |
|
|
2023
Q4 | $15.7M | Buy |
60,626
+13,796
| +29% | +$3.39M | 0.02% | 372 |
|
|
2023
Q3 | $11.8M | Buy |
46,830
+4,209
| +10% | +$1.13M | 0.02% | 401 |
|
|
2023
Q2 | $12.2M | Sell |
42,621
-2,968
| -7% | -$884K | 0.02% | 419 |
|
|
2023
Q1 | $12.7M | Sell |
45,589
-474
| -1% | -$131K | 0.02% | 406 |
|
|
2022
Q4 | $12.8M | Sell |
46,063
-7,491
| -14% | -$2.12M | 0.02% | 368 |
|
|
2022
Q3 | $14.3M | Sell |
53,554
-11,486
| -18% | -$2.44M | 0.02% | 366 |
|
|
2022
Q2 | $13.3M | Buy |
65,040
+20,338
| +45% | +$4.16M | 0.02% | 391 |
|
|
2022
Q1 | $9.41M | Buy |
44,702
+197
| +0.4% | +$42.8K | 0.01% | 470 |
|
|
2021
Q4 | $10.7M | Buy |
44,505
+4,691
| +12% | +$1.21M | 0.01% | 467 |
|
|
2021
Q3 | $11.3M | Sell |
39,814
-6,627
| -14% | -$2.17M | 0.02% | 442 |
|
|
2021
Q2 | $16.1M | Sell |
46,441
-1,128
| -2% | -$342K | 0.02% | 372 |
|
|
2021
Q1 | $13.3M | Sell |
47,569
-30,622
| -39% | -$8.26M | 0.02% | 377 |
|
|
2020
Q4 | $19.1M | Buy |
78,191
+2,489
| +3% | +$642K | 0.04% | 260 |
|
|
2020
Q3 | $21.5M | Sell |
75,702
-4,716
| -6% | -$1.32M | 0.05% | 227 |
|
|
2020
Q2 | $21.5M | Buy |
80,418
+60,611
| +306% | +$18.2M | 0.06% | 223 |
|
|
2020
Q1 | $6.27M | Sell |
19,807
-6,311
| -24% | -$1.92M | 0.02% | 319 |
|
|
2019
Q4 | $7.75M | Sell |
26,118
-4,324
| -14% | -$1.2M | 0.02% | 368 |
|
|
2019
Q3 | $7.09M | Buy |
30,442
+630
| +2% | +$147K | 0.02% | 382 |
|
|
2019
Q2 | $6.97M | Sell |
29,812
-7,928
| -21% | -$1.83M | 0.02% | 370 |
|
|
2019
Q1 | $8.92M | Sell |
37,740
-361,413
| -91% | -$114M | 0.02% | 394 |
|
|
2018
Q4 | $120M | Buy |
399,153
+69,178
| +21% | +$22.1M | 0.32% | 86 |
|
|
2018
Q3 | $117M | Buy |
329,975
+295,060
| +845% | +$102M | 0.28% | 97 |
|
|
2018
Q2 | $10.1M | Buy |
34,915
+832
| +2% | +$234K | 0.03% | 324 |
|
|
2018
Q1 | $9.33M | Sell |
34,083
-30,461
| -47% | -$9.46M | 0.02% | 347 |
|
|
2017
Q4 | $20.6M | Buy |
+64,544
| New | +$20.7M | 0.05% | 257 |
|
|
2016
Q3 | – | Sell |
-8,636
| Closed | -$2.09M | – | 672 |
|
|
2016
Q2 | $2.09M | Sell |
8,636
-534
| -6% | -$141K | 0.01% | 429 |
|
|
2016
Q1 | $2.39M | Buy |
9,170
+1,790
| +24% | +$473K | 0.02% | 331 |
|
|
2015
Q4 | $2.26M | Sell |
7,380
-2,210
| -23% | -$635K | 0.01% | 395 |
|
|
2015
Q3 | $2.8M | Sell |
9,590
-22,630
| -70% | -$7.47M | 0.02% | 361 |
|
|
2015
Q2 | $13M | Sell |
32,220
-13,555
| -30% | -$5.44M | 0.07% | 226 |
|
|
2015
Q1 | $19.3M | Sell |
45,775
-7,655
| -14% | -$3.02M | 0.1% | 192 |
|
|
2014
Q4 | $18.1M | Sell |
53,430
-24,110
| -31% | -$7.8M | 0.09% | 182 |
|
|
2014
Q3 | $25.7M | Sell |
77,540
-26,005
| -25% | -$8.57M | 0.13% | 150 |
|
|
2014
Q2 | $32.6M | Sell |
103,545
-7,280
| -7% | -$2.19M | 0.15% | 133 |
|
|
2014
Q1 | $33.9M | Buy |
110,825
+10,210
| +10% | +$3.24M | 0.17% | 132 |
|
|
2013
Q4 | $28.1M | Buy |
100,615
+7,207
| +8% | +$1.86M | 0.14% | 154 |
|
|
2013
Q3 | $22.5M | Buy |
93,408
+4,066
| +5% | +$910K | 0.11% | 174 |
|
|
2013
Q2 | $19.2M | Buy |
+89,342
| New | +$19.1M | 0.09% | 196 |
|
Other funds holding BIIB
Mackenzie Financial's BIIB Position: Q2 2026 in Review
Mackenzie Financial increased its Biogen (BIIB) stake by 21% in Q2 2026, buying an estimated $2.86M and bringing the position to 86,394 shares worth $18.7M. The position accounts for 0.02% of the portfolio, ranked #463.
Mackenzie Financial first reported a position in BIIB in Q2 2013 and has held it in 48 quarters since. The position peaked at $120M in Q4 2018. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Mackenzie Financial held 86,394 shares of Biogen worth $18.7M as of Q2 2026.
- Mackenzie Financial bought 14,962 Biogen shares in Q2 2026, an estimated $2.86M.
- Biogen made up 0.02% of Mackenzie Financial's portfolio in Q2 2026, its #463 holding.
- Mackenzie Financial first reported a position in Biogen in Q2 2013 and has held it in 48 quarters since.
- Mackenzie Financial's Biogen position peaked at $120M in Q4 2018.
- 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.